血清素 - 5 - O - 羧甲基 - 甘氨酰[125I]酪氨酸酰胺标记人皮质中的5 - HT1Dβ受体亚型。
Serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide labels the 5-HT1D beta receptor subtype in human cortex.
作者信息
Beer M S, Middlemiss D N
机构信息
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
出版信息
Eur J Pharmacol. 1993 Sep 28;242(2):195-8. doi: 10.1016/0014-2999(93)90080-2.
This study, carried out in human cerebral cortical membranes, confirms previous findings in human substantia nigra that serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide ([125I]GTI) labels a homogeneous population of recognition sites consistent with a 5-HT1D receptor pharmacology. In addition the results indicate that, under the assay conditions described, [125I]GTI specifically labels the 5-HT1D beta recognition site since ketanserin and ritanserin display a low affinity consistent with their activities at this subtype of the 5-HT1D receptor.
这项在人脑皮质膜上进行的研究证实了先前在人黑质中的发现，即血清素 - 5 - O - 羧甲基 - 甘氨酰[125I]酪氨酸酰胺（[125I]GTI）标记了与5 - HT1D受体药理学一致的同质识别位点群体。此外，结果表明，在所描述的测定条件下，[125I]GTI特异性标记5 - HT1Dβ识别位点，因为酮色林和利坦色林显示出低亲和力，这与其在5 - HT1D受体该亚型上的活性一致。
Zotero 插件